Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03776747 · ClinicalTrials.gov registry record · Phase 4
Repeatability in Hyperpolarized 3-Helium With MRI
A Phase 4 study, sponsored by Eric A. Hoffman.
- Completed
- Registry status
- Phase 4
- Development phase
- 18
- Enrollment target
NCT03776747: Completed Phase 4 study, sponsored by Eric A. Hoffman.
NCT03776747 is a Phase 4 study that has completed, run by Eric A. Hoffman. The registered enrollment target is 18 participants, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (97% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03776747, a Phase 4 study, has completed, sponsored by Eric A. Hoffman.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 18 participants
- Enrollment target
Study Summary
The main purpose of this study is to assess and test the reproducibility and results of hyperpolarized 3-Helium gas as a contrast agent with Magnetic Resonance Imaging (MRI) of the lungs in healthy adult subjects.
Primary Outcome
Validate the intrinsic variability of ADC (cm2/s) as a function of normal procedural and physiological changes in an attempt to standardize the use of the biomarker in future assessments of pulmonary pathologies.
Interventions
- DRUG Prone hyperpolarized 3 helium gas scan
- DRUG Supine hyperpolarized 3 helium gas scan
- DIAGNOSTIC_TEST Vitals
- DIAGNOSTIC_TEST Pulmonary Function Tests
- DIAGNOSTIC_TEST Initial protocol MRI scan
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 18 participants |
| Start Date | 2008-07-22 |
| Est. Completion | 2012-06 |
| Phase | Phase 4 |
What the finished NCT03776747 record still lists
NCT03776747 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 18 participants, a relatively small participant target, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (97% lower).
The record links to 0 conditions, and to 5 interventions - of which Prone hyperpolarized 3 helium gas scan is the first listed.
NCT03776747 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03776747 about?
NCT03776747 is a clinical study titled "Repeatability in Hyperpolarized 3-Helium With MRI". The main purpose of this study is to assess and test the reproducibility and results of hyperpolarized 3-Helium gas as a contrast agent with Magnetic Resonance Imaging (MRI) of the lungs in healthy adult subjects.
What is the current status of trial NCT03776747?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 18 participants. The study started on 2008-07-22. Estimated completion is 2012-06.
What interventions are being tested in trial NCT03776747?
The interventions under investigation include: Prone hyperpolarized 3 helium gas scan (DRUG), Supine hyperpolarized 3 helium gas scan (DRUG), Vitals (DIAGNOSTIC_TEST), Pulmonary Function Tests (DIAGNOSTIC_TEST), Initial protocol MRI scan (DIAGNOSTIC_TEST).
Who is sponsoring clinical trial NCT03776747?
This trial is sponsored by Eric A. Hoffman, which has 5 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT03776747's enrollment target sits among peer trials
18 1842nd of 2000 higher than 147 of 2,000 other Phase 4 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 4 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01245179 · 18 participants · Phase 1
Study of Panobinostat (LBH589) in Patients With Sickle Cell Disease
- NCT01999361 · 18 participants · NA
Prevention of de Novo Allosensitization in Islet Transplant Recipients Following Complete Graft Loss
- NCT02359825 · 18 participants · Phase 1
Nerve Repair Using Hydrophilic Polymers to Promote Immediate Fusion of Severed Axons and Swift Return of Function
- NCT02870244 · 18 participants · Phase 1
Adoptive T Cell Immunotherapy for Advanced Melanoma Using Engineered Lymphocytes
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI